2018
DOI: 10.1515/cclm-2018-0181
|View full text |Cite
|
Sign up to set email alerts
|

Personalized laboratory medicine: a patient-centered future approach

Abstract: In contrast to population-based medical decision making, which emphasizes the use of evidence-based treatment strategies for groups of patients, personalized medicine is based on optimizing treatment at the level of the individual patient. The creation of molecular profiles of individual patients was made possible by the advent of "omics" technologies, based on high throughput instrumental techniques in combination with biostatistics tools and artificial intelligence. The goal of personalized laboratory medici… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
11
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(12 citation statements)
references
References 49 publications
0
11
0
1
Order By: Relevance
“…The HS phenotype may also be modified by co-occurrence with other disorders like glucose-6-phosphate dehydrogenase (G6PD) and Gilbert syndrome ( Aggarwal et al, 2019 ; Zou et al, 2020 ). Application of next-generation sequencing (NGS) has led to impressive progress in genetic disorder diagnostics, and it has provided unprecedented benefits for both personalized laboratory medicine and patients with rare genetic disorders ( Di Resta and Ferrari, 2018 ; Prodan Zitnik et al, 2018 ). NGS has promoted HS molecular diagnosis compared to clinical practice, including both targeted panel and whole exome sequencing (WES) ( Xue et al, 2019 ; Qin L. et al, 2020 ).…”
Section: Introductionmentioning
confidence: 99%
“…The HS phenotype may also be modified by co-occurrence with other disorders like glucose-6-phosphate dehydrogenase (G6PD) and Gilbert syndrome ( Aggarwal et al, 2019 ; Zou et al, 2020 ). Application of next-generation sequencing (NGS) has led to impressive progress in genetic disorder diagnostics, and it has provided unprecedented benefits for both personalized laboratory medicine and patients with rare genetic disorders ( Di Resta and Ferrari, 2018 ; Prodan Zitnik et al, 2018 ). NGS has promoted HS molecular diagnosis compared to clinical practice, including both targeted panel and whole exome sequencing (WES) ( Xue et al, 2019 ; Qin L. et al, 2020 ).…”
Section: Introductionmentioning
confidence: 99%
“…The possible reason for this might be that the patients with FH in our study do not have any phenotypes characteristics to inflammation; consistent with the nature of FH, as it is a frequent disease (1/220-250) with a high variation in phenotypic expression associated with ASCVD ( Alhababi and Zayed, 2018 ; Perez-Calahorra et al, 2019 ). Also, in era of personalized medicine, it is significant to identify the possible targeted therapy using advanced omics technologies ( Prodan Žitnik et al, 2018 ).…”
Section: Discussionmentioning
confidence: 99%
“…In addition, genetic testing provided an answer about the family history of the patient 2 and useful information when parents are planning for a new child. Therefore, genetic testing, especially next generation sequencing, is an established test method in clinical managements (40,41). Integrating genetic and clinical data enhances the care quality for the patients as well as their families (40)(41)(42)(43).…”
Section: Discussionmentioning
confidence: 99%